Compare Extra Space Storage, Inc. (EXR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Sana Biotechnology Inc — how do they compare? Extra Space Storage, Inc. trades at $134.65 (market cap $28.12B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Extra Space Storage, Inc. is far larger — about 33.6× Sana Biotechnology Inc's market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Sana Biotechnology Inc for 23 Days on average.
| EXR | SANA | |
|---|---|---|
Market Cap | $28.12B | $836.71M |
Volume | 2,595,579 | 4,507,444 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $5.92 |
52-Week Low | $126.67 | $2.68 |
Typical Hold Time | 109 Days | 23 Days |
Enterprise Value | $41.84B | $749.96M |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $133.12, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin remains healthy at 27.79%. Analyst consensus is split evenly between Buy and Hold, with a price target of $158.33 implying upside. Recent news highlights leadership transition and positive operational performance.
The outlook is balanced: solid profitability and growth support upside, but high valuation multiples and bearish technicals pose near-term risks. Key catalysts include Q3 earnings and execution under new leadership. Risks involve interest rate sensitivity and competitive pressures in the REIT sector.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
